Table 2 Criteria for recipient (patient) enrollment

Inclusion Criteria

Age ≥ 18

Histologic confirmation of the following leukemias/lymphomas:

• Mantle cell lymphoma with Ki-67>30%

• Diffuse Large Cell Lymphoma

• Burkitts Lymphoma

• Systemic T Cell Lymphomas

• Acute Myeloid Leukemia

• Acute Lymphoblastic Leukemia

Recurrence or progression of disease after at least 1 prior standard treatment

Progression of disease within 6 months of last treatment

No available curative treatment option

≥ 4-weeks since prior chemotherapy or radiation (Exception: Hydroxyurea may be utilized up to 48 hours prior to treatment)

Life expectancy of 2 months at treatment initiation

≥ 6 months post autologous stem cell transplant

DLCO ≥ 40% with no symptomatic pulmonary disease.

LVEF ≥ 40% by MUGA or echocardiogram.

Creatinine ≤ 2.0 mg/dl, Total bilirubin <1.5x the upper limit of normal (ULN), AST < 3x ULN

Non-pregnant and willing to use appropriate birth control during study period

Exclusion criteria

Previous allogeneic stem cell transplant

Previous purine analog (fludarabine, pentostatin, 2-CDA) or alemtuzumab within 1 year of entering the study

CML, CLL, multiple myeloma, and indolent lymphoma (follicular lymphoma, marginal zone lymphoma)

HLA antibodies to donor HLA type

HIV-1 or 2 positive

Oxygen dependant COPD

Failure to demonstrate adequate compliance with medical therapy and follow-up

Significant medical or psychiatric illness that would impair the ability to participate in protocol therapy

Active systemic infection